Jelena Telenius

Jelena Telenius

Auto-generated profile, based on publicly available information

Jelena Telenius

MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2016 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DHDeborah Hay
Deborah Hay
JHJim R Hughes
Jim R Hughes
CBChristian Babbs
Christian Babbs
JDJames O J Davies
James O J Davies
BGBryony J Graham
Bryony J Graham
DHDouglas R Higgs
Douglas R Higgs

23 November 2015 in Nature Methods
Verified
Journal Article
Open access
PDF file
JDJames O J Davies
James O J Davies
JTJelena M Telenius
Jelena M Telenius
SMSimon J McGowan
Simon J McGowan
NRNigel A Roberts
Nigel A Roberts
STStephen Taylor
Stephen Taylor
JHJim R Hughes
Jim R Hughes
Pooling barcoded 3C libraries and simultaneously capturing interactions at many loci of interest generates reproducible cis- and trans-interaction maps at high resolution from low amounts of input material. This allows for the comparison of interactions in different cell types using common software designed for differential analysis of sequence count data, rather than requiring software specifically designed for 3C experiments. Methods for analyzing chromosome conformation in mammalian cells are either low resolution or low throughput and are technically challenging. In next-generation (NG) Capture-C, we have redesigned the Capture-C method to achieve unprecedented levels of sensitivity and reproducibility. NG Capture-C can be used to analyze many genetic loci and samples simultaneously. High-resolution data can be produced with as few as 100,000 cells, and single-nucleotide polymorphisms can be used to generate allele-specific tracks. The method is straightforward to perform and should greatly facilitate the investigation of many questions related to gene regulation as well as the functional dissection of traits examined in genome-wide association studies.

29 October 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AOA. Marieke Oudelaar
A. Marieke Oudelaar
JDJames O. J. Davies
James O. J. Davies
LHLars L. P. Hanssen
Lars L. P. Hanssen
JTJelena M. Telenius
Jelena M. Telenius
RSRon Schwessinger
Ron Schwessinger
JHJim R Hughes
Jim R Hughes

21 August 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DJDanuta M. Jeziorska
Danuta M. Jeziorska
RMRobert J. S. Murray
Robert J. S. Murray
MGMarco De Gobbi
Marco De Gobbi
RGRicarda Gaentzsch
Ricarda Gaentzsch
DGDavid Garrick
David Garrick
Cristina TufarelliCristina Tufarelli
Cristina Tufarelli
Significance: The human genome contains ∼30,000 CpG islands (CGIs), long stretches (0.5–2 kb) of DNA with unusually elevated levels of CpG dinucleotides. Many occur at genes' promoters, and their DNA nearly always remains unmethylated. Conversely, intragenic CGIs are often, but not always, methylated, and thus inactive as internal promoters. The mechanisms underlying these contrasting patterns of CGI methylation are poorly understood. We show that methylation of intragenic CGIs is associated with transcription running across the island. Whether or not a particular intragenic CGI becomes methylated during development depends on its transcriptional activity relative to that of the gene within which it lies. Our findings explain how intragenic CGIs are epigenetically programmed in normal development and in human diseases, including malignancy.

1 October 2019 in Developmental Cell
Verified
Journal Article
Open access
RWRuth M. Williams
Ruth M. Williams
ICIvan Candido-Ferreira
Ivan Candido-Ferreira
EREmmanouela Repapi
Emmanouela Repapi
DGDaria Gavriouchkina
Daria Gavriouchkina
USUpeka Senanayake
Upeka Senanayake
TSTatjana Sauka-Spengler
Tatjana Sauka-Spengler
Precise control of developmental processes is encoded in the genome in the form of gene regulatory networks (GRNs). Such multi-factorial systems are difficult to decode in vertebrates owing to their complex gene hierarchies and dynamic molecular interactions. Here we present a genome-wide in vivo reconstruction of the GRN underlying development of the multipotent neural crest (NC) embryonic cell population. By coupling NC-specific epigenomic and transcriptional profiling at population and single-cell levels with genome/epigenome engineering in vivo, we identify multiple regulatory layers governing NC ontogeny, including NC-specific enhancers and super-enhancers, novel trans-factors, and cis-signatures allowing reverse engineering of the NC-GRN at unprecedented resolution. Furthermore, identification and dissection of divergent upstream combinatorial regulatory codes has afforded new insights into opposing gene circuits that define canonical and neural NC fates early during NC ontogeny. Our integrated approach, allowing dissection of cell-type-specific regulatory circuits in vivo, has broad implications for GRN discovery and investigation.

26 June 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
LGLaura C Godfrey
Laura C Godfrey
NCNicholas T. Crump
Nicholas T. Crump
RTRoss Thorne
Ross Thorne
ILI-Jun Lau
I-Jun Lau
EREmmanouela Repapi
Emmanouela Repapi
TMTom Milne
Tom Milne
Enhancer elements are a key regulatory feature of many important genes. Several general features including the presence of specific histone modifications are used to demarcate potentially active enhancers. Here we reveal that putative enhancers marked with H3 lysine 79 (H3K79) di or trimethylation (me2/3) (which we name H3K79me2/3 enhancer elements or KEEs) can be found in multiple cell types. Mixed lineage leukemia gene (MLL) rearrangements (MLL-r) such as MLL-AF4 are a major cause of incurable acute lymphoblastic leukemias (ALL). Using the DOT1L inhibitor EPZ-5676 in MLL-AF4 leukemia cells, we show that H3K79me2/3 is required for maintaining chromatin accessibility, histone acetylation and transcription factor binding specifically at KEEs but not non-KEE enhancers. We go on to show that H3K79me2/3 is essential for maintaining enhancer-promoter interactions at a subset of KEEs. Together, these data implicate H3K79me2/3 as having a functional role at a subset of active enhancers in MLL-AF4 leukemia cells.